T he current recommendations for blood pressure target values and pharmacological treatment of arterial hypertension in older people are heterogeneous (1, 2) . The 2017 guideline of the American College of Cardiology recommends a new target value of systolic blood pressure <130 mmHg for persons ≥ 65 years living at home (3) . For the same age group, the recently published guidelines of the European Society of Cardiology (ESC), state a target range of 130 to 139 mmHg for systolic pressure (level of evidence A) (4) . The German Hypertension League and the German College of General Practitioners and Family Physicians (DEGAM) also recommend that the blood pressure should be <140/90 mmHg in the elderly (5-7). However, the DEGAM describes the research data on antihypertensive treatment in older patients as inadequate (6) . Management of high blood pressure is particularly challenging in frail, elderly persons owing to the potential complications and the problem of tolerance. The above-mentioned American guideline (3) differentiates older patients primarily by morbidity, age, and institutionalization, but not by degree of frailty. In contrast, the current ESC guideline distinguishes between fit, independent patients and frail patients (4) . While it can be assumed that older hypertensive patients who are not frail can be treated analogously to younger age groups, one has to question whether frail elderly patients benefit from such a therapy (8) .
But what is "frailty"? The term has never been clearly defined since its introduction in 1992 and remains controversial. While the explanatory model proposed by Fried et al. (9) defines frailty mainly in physical terms such as measurements of grip strength, undesired weight loss, physical activity, and gait speed, the Frailty Index (FI) of Rockwood et al. (10) also embraces cognitive parameters, comorbidity, and malnutrition. In order to achieve comparable characterization of older participants in randomized controlled trials (RCTs), in 2015 the European Medicines Agency (EMA) suggested measuring walking speed and carrying out the Short Physical Performance Battery (11) .
At present, both the American and European guidelines leave the decision on antihypertensive treatment of frail, older adults to the treating physician (3, 4) . Although frailty already plays a role in guideline recommendations, the existing systematic reviews
Summary
Background: It is debated whether the treatment goals and decision-making algorithms for elderly patients with hypertension should be the same as those for younger patients. The American and European guidelines leave decisions about antihypertensive treatment in frail, institutionalized patients up to the treating physician. We therefore systematically searched the literature for publications on the phamacotherapy of arterial hypertension in frail patients.
Methods: The MEDLINE, Embase, and Central databases were systematically searched for randomized, controlled trials (RCTs) and non-randomized studies, including observational studies, on the pharmacotherapy of arterial hypertension in elderly patients since the introduction of the concept of frailty, published over the period 1992-2017.
Results: Out of 19 282 citations for randomized, controlled trials and 5659 for non-randomized trials and observational studies, four RCTs and three observational studies were included in the further analysis. The included RCTs showed a trend towards a benefit from pharmacotherapy of hypertension in frail patients with respect to mortality, cardiovascular disease, functional status, and quality of life. On the other hand, some of the observational studies indicated a lower rate of falls and lower mortality among patients who received no antihypertensive treatment.
Conclusion: In view of the conflicting findings of RCTs and non-randomized studies, the lower representation of frail subjects in RCTs, and the high risk of bias in nonrandomized studies, the findings of the studies included in this review do not enable the formulation of any strictly evidence-based treatment recommendations. As a rule of thumb, the authors propose that a target systolic blood pressure of <150 mmHg should be aimed at in patients whose gait speed is less than 0.8 m/s, while a target range of 130-139 mmHg can be set for patients over age 80 who are no more than mildly frail.
have only considered age. For this reason, we took frailty into account in a systematic assessment of the evidence regarding the pharmacological treatment of arterial hypertension.
Method
The MEDLINE, Embase, and Central databases were searched for relevant records in the period 1 January 1992 to 31 December 2017 (PROSPERO CRD42017067253) (12) . Two reviewers (VM, SB) independently carried out the following steps:
• Selection of studies • Data extraction • Assessment of the risk of bias in the primary studies Any disagreements between the reviewers were resolved by discussion or by a third person (MD, DD). Included for analysis were RCTs that investigated the effects of pharmacological treatment of hypertension on the endpoints functionality, mortality, morbidity, or quality of life in relation to physical frailty. Nonrandomized controlled trials (non-RCTs) were also included if they analyzed physical frailty as effect modifier of antihypertensive treatment for the abovementioned endpoints (for further details, please refer to the eMethods supplement). Physical frailty was evaluated systematically on the basis of the functional assessments (e.g., of mobility or activities of daily living [ADL] ) that had been performed (13) .
Results
The survey revealed 19 282 records for RCTs based on the titles and abstracts, of which 39 were identified as potentially relevant. For non-RCTs and observational studies, 41 of 5659 records were judged potentially relevant. After full-text screening, four RCTs (14-19) and three prospective longitudinal cohort studies (20-22) were included for analysis. One reanalysis of an RCT (23) was identified and included after an additional search for the first and last authors of these seven studies. Details of the studies included and their results are presented in • SHEP (Systolic Hypertension in the Elderly Program) (19) • SPRINT (Systolic Blood Pressure Intervention Trial) (14, 15, 23) HYVET investigated the interaction between drug treatment (a combination of slow-release indapamide 1.5 mg ± perindopril 2-4 mg) and frailty in patients 80 years of age or older with a systolic blood pressure >160 mmHg (16). In this context the available data suggest that the protective effect of antihypertensive treatment-with regard to the incidence of strokes and of fatal or non-fatal cardiovascular events-could be greater with increasing frailty. Further analysis of the HYVET data with the change in frailty during the first 24 months as endpoint showed no significant difference, but the outcome tended to be better in the intervention group (17). The risk of bias for HYVET was found to be predominantly low. However, the description of random sequence generation was insufficient (eTable 2).
In DANTE, short-term discontinuation of antihypertensive treatment in patients ≥ 75 years of age with mild cognitive deficits (Mini-Mental State Examination [MMSE] score 21-27) did not improve cognition or functionality (ADL) after 16 weeks (18). The treatment for hypertension also showed no differences in effect on cognition between groups with and without restricted ADL. The risk of bias was predominantly low, but there was no blinding of participants or study personnel (18) (eTable 2).
SHEP, published in 1991, was the first American RCT to show the protective effect of antihypertensive treatment (chlorthalidone ± atenolol) against fatal and nonfatal stroke compared with placebo (25). A post-hoc analysis 25 years after the end of the study demonstrated no modification of the effect by self-reported functional limitations (19) . There were
The clinical perspective
• Before the commencement of treatment, older patients should be screened for physical frailty in terms of gait speed or Short Physical Performance Battery (SPPB) score.
• The evidence is insufficient for patients with severe physical frailty. Based on current knowledge, for patients with a gait speed of <0.8 m/s we recommend a target systolic blood pressure of <150 mmHg. Adverse effects, particularly orthostatic hypotension, should be avoided if at all possible.
• In patients >80 years of age who are not or only slightly frail, the target systolic blood pressure should be 130-139 mmHg. It goes without saying that the patient's tolerance of the treatment should be taken into account in each individual case.
• The greater the frailty and functional limitations of the patients, the more closely they should be monitored after any change in treatment.
signs that the treatment increased the risk of occurrence of the secondary endpoints overall mortality, cardiovascular mortality, myocardial infarction, and stroke in functionally impaired patients. The risk of bias was predominantly low; however, the risk was unclear for random sequence generation and high for incomplete outcome data (eTable 2).
SPRINT examined, in a subanalysis, the effects on the primary endpoints mortality and cardiovascular disease of intensive treatment for high blood pressure (<120 mmHg) compared with standard treatment (<140 mmHg) in patients aged 75 years and over (14) . Intense lowering of blood pressure protected against cardiovascular events regardless of gait speed. Further analyses of the SPRINT data showed no differences between the groups for decrease in gait speed over the following 3 years (15). For intensive treatment the risk of death was lower in patients without restricted mobility. However, the protective effect did not attain significance in those with restricted mobility. Patients who reported worse physical quality of life at the beginning of the study showed a more rapid decrease in gait speed than those whose self-assessment was better (15). After stratification by frailty, no significant difference in subjective quality of life was observed between the two groups (23). The risk of bias was predominantly unclear due to inadequacies in the description of random sequence generation and in blinding (eTable 2) (26, 27). Health ABC investigated the association between consumption of antihypertensive medications and recurrent falls over a period of 7 years in 2948 community-dwelling, initially well-functioning older adults (21). A sensitivity analysis showed no effect modification by gait speed. The risk of bias was assessed as moderate.
Non-randomized controlled trials
One of the analyses in the Medicare Current Beneficiary Survey showed that administration of intensive drug treatment for high blood pressure was associated with an increased risk of serious fall injuries in 4961 Medicare patients ≥ 70 years of age. The risk was significantly higher in patients who were physically frail (as defined by falls in the foregoing year); however, there was no essential difference in risk between the groups with moderate and high decreases in blood pressure (20). The risk of bias was assessed as serious.
The Jerusalem Longitudinal Study examined the association between medicinal treatment of arterial hypertension and overall mortality in patients over 90 years of age depending on frailty, assessed in terms of ADL and grip strength (22). There were trends towards slightly lower mortality in untreated persons with hypertension and higher mortality in those who received treatment for hypertension compared with normotensive persons who did not receive treatment. The protective effect without treatment was greater among the participants with better physical functionality (22). The risk of bias was assessed as moderate
Discussion
Although the term "frailty" was introduced as long ago as 1992 (28), our literature search for this review found only a small number of studies that characterized their participants in this respect. The findings of the RCTs we identified show that even patients with pronounced physical frailty may benefit from treatment of hypertension in terms of mortality, cardiovascular disease, functionality, and quality of life. However, because the risk of bias was often unclear, the proportion of participants with marked functional limitations mostly low, and the heterogeneity of the studies analyzed high, the quality of the evidence does not permit derivation of treatment recommendations. The quality of the nonRCTs we identified is also too low to evaluate whether physical frailty can be considered an effect modifier.
HYVET and SPRINT can be described as landmark RCTs for our study question, as they were the first to characterize the participants precisely in terms of frailty (eTable 3). The results show that antihypertensive treatment has a protective effect even in physically frail older patients. However, the subgroup analyses lacked the necessary statistical power for robust conclusions. Furthermore, it is questionable to what extent the RCTs' selected patient populations reflect the the reality of prescription practice. For instance, SPRINT excluded patients with diabetes, symptomatic heart failure, orthostatic hypotension, or
TABLE 1b
Characteristics of the non-randomized controlled trials included for analysis The risk of bias in SPRINT was predominantly unclear, with inadequacies in the description of random sequence generation and in blinding of study personnel (26, 27). Gait speed and mobility restriction were not considered endpoints at the beginning of the study according to the registered study protocol (Clini calTrials.gov identifier: NCT01206062). Since all the study results display wide confidence intervals, the precision of the estimate of effect is low. Both HYVET and SPRINT were terminated prematurely, so the effect of the intervention may be overestimated (31) . Moreover, in HYVET the FI, used to classify functionality, was also calculated for participants in whom not all, or not at least half, of the items were present (16). Therefore, the classification of the participants may be erroneous in this respect.
In addition, a higher risk of bias must be assumed for the non-RCTs. The results presented are of little assistance in deciding on differential treatment depending on physical frailty. Here too, many of the study participants had only slight functional limitations or none at all (21). While the known risk of a higher rate of falls with more intensive treatment for high blood pressure was confirmed, functional limitation seems to increase the risk (20). Many nonRCTs had to be excluded from our analysis either because they merely used the measured blood pressure as a surrogate for antihypertensive treatment or because they investigated neither greater functional limitation nor physical frailty as effect modifier. Only the PARTAGE study looked at the interaction between systolic blood pressure and the number of antihypertensive medications in residents of nursing homes. The results showed that patients with systolic blood pressure <130 mmHg who were taking at least two antihypertensive medications had the highest risk of death (32). Unfortunately there was no stratification of participants according to physical frailty, so this study had to be excluded.
The PARTAGE findings are in accordance with those of other epidemiological studies that postulate a J-shaped association between blood pressure and mortality. However, there is a distinct danger of reverse causation. For example, persons over 80 years old in Great Britain were found to be at greater risk of death with systolic blood pressure <120 mmHg (33). On examination of the blood pressure over time, however, a sharp drop in pressure was found particularly in the last 2 years of life, independent of antihypertensive treatment. The association may thus be explained by an as yet pathophysiologically unexplained blood pressure decrease up to 2 years before death, rather than by treatment for hypertension or by the blood pressure at the beginning of the study (33, 34) . In the absence of sensitivity analyses to exclude reverse causation, results should therefore always be viewed critically. However, these analyses point to a basic problem: in the months before death, treatments may be no longer indicated or required but are nevertheless continued (33).
The target systolic blood pressure of 130-139 mmHg in the new ESC guideline for persons over 80 years of age may need critical reevaluation for patients with severe or very severe physical limitations (4). In HYVET, for instance, there was a reduction in mortality for target pressures <150 mmHg (16). More research is needed to ascertain to what extent a further reduction of the target to <140 mmHg would provide further protection. The ongoing INFINITY study ("Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People"; ClinicalTrials.gov NCT01650402) will also achieve little with regard to persons with severe to very severe limitations, because it excluded patients with signs of physical frailty (Short Physical Performance Battery score <10 points).
Strengths and limitations
The strength of this systematic review is that for the first time the available literature-both RCTs and nonRCTs, including observational studies-on the treatment of hypertension has been evaluated taking into account physical frailty. We strove to ensure identification of all relevant publications by hand-searching the reference lists of systematic reviews on antihypertensive treatment in older patients (35-37) and further landmark studies (eTable 3). However a small risk remains that single subgroup-analyses were not considered. Another critical point is the method used to identify physically frail, functionally impaired patients. The heterogeneity of the definitions of frailty highlighted the considerable differences between functionoriented assessments, cognition-oriented assessments, and deficit models such as Rockwood's cumulative FI (used in SPRINT and HYVET). For instance, the FI in SPRINT features hardly any aspects of physical function. Moreover, post-hoc subgroup analyses limit the robustness of the results. In most non-RCTs not all confounding factors can be taken into account. Assessment of publication bias was not feasible owing to the small number of studies identified.
Summary
Even after a systematic analysis of the published data with regard to physical frailty, questions remain open. The SPRINT and HYVET findings seem to show that antihypertensive treatment as recommended in the prevailing guidelines may also be indicated in this group of patients. Whether patients with severe physical frailty were included in these studies is uncertain because of the deficit-oriented FI they used. Furthermore, these two studies are not representative due to their exclusion criteria. Among the non-RCTs only a small number of studies have analyzed both drug treatment and physical function in detail. To ensure reliable characterization and facilitate comparability among studies, not only should older members of the population be included in future research, as stated so often before, but systematically evaluated geriatric assessment instruments should be used. This is the only way in which modification of effects by physical frailty can be evaluated. Moreover, in order to fill the gaps in evidence, not only classical clinical studies but also deprescribing RCTs and new methodological approaches including prospective meta-analyses should be carried out in established research networks. 
Key messages
• Although the term "frailty" was introduced as early as 1992, the physical function and/or frailty of older study participants is hardly ever documented in randomized controlled trials (RCTs) or non-RCTs.
• The lower target blood pressures in the current guidelines must be critically reconsidered and, as the guidelines state, the target must be decided on an individual basis for each patient.
• When interpreting the results with regard to a possible J-shaped association between blood pressure and mortality in observational studies, one should, even in the presence of conceivable pathophysiology, take the methodological limitations (reverse causation) into account.
• To improve the characterization of older persons in clinical studies and observational studies with regard to their functionality, validated instruments for functional assessment should be used. We agree with the European Medicines Agency that at least gait speed and the Short Physical Performance Battery should be included. T he search strategy was based on a validated filter for geriatric patients (e2) and established search filters for randomized controlled trials (RCTs) (e3) and non-RCTs including observational studies (e4), supplemented with further search terms related to functionality and hypertension (eBox 2). The search was carried out with no language restrictions of publication. In addition, the reference lists of national and international guidelines were handsearched. Finally, a search was conducted for citations of the first and last author of all studies included for analysis over the whole period. The permitted comparisons were antihypertensive treatment versus placebo, no treatment, or other drug treatment. Comparisons of different target blood pressures were also included. Observational studies that exclusively investigated the measured blood pressure values as the exposure of interest were excluded.
To optimize comparability of the estimation of functionality across various studies/indications, we analyzed all of the functionality scores (including a frailty index) used in studies and arranged them into a comparative system (13) . The references were selected with the aid of Covidence, which is a screening software from the Cochrane Collaboration with various functions that accelerate the selection process.
The studies chosen for full-text screening were those on pharmacological treatment of hypertension that referred to assessment of functionality in the abstract. The risk of bias was assessed by means of the Cochrane Risk of Bias Tool (e3) for RCTs. The non-RCTs were assessed for risk of bias according to ROBINS-I (e5) (eTable 4) and reported according to STROBE (e6) (eTable 5).
eMETHODS eBOX 1 Effect modification
Effect modification is present when the influence of a factor (in our case the drug treatment of arterial hypertension) on an endpoint is modified by the presence of another factor, the so-called effect modifier (in our case physical frailty). One can also talk of an interaction between the exposure of interest and the effect modifier (e1). A question increasingly being asked in the field of clinical epidemiology is whether the effects of a treatment on various endpoints in elderly populations could be modified by frailty.
There are several ways of investigating an interaction. First, one can test, in the statistical model, whether an interaction term, made up of the variable of interest and the possible effect modifier (interaction term = variable*effect modifier), is relevant. If the interaction is significant, the statistical model must contain the interaction term; this, however, complicates interpretation of the effects of the variable. Another way of investigating a possible interaction is to conduct stratified analyses-stratified by the effect modifier (e.g., frail versus not frail). By this means the effects of the variable of interest on the various strata are calculated and contrasted. However, stratification reduces the number of observations per group (stratum), so the statistical power may be affected. 
III

Study question
What is the effect of antihypertensive treatment in older persons aged 60 years and over? Does antihypertensive treatment in patients aged 60 to 79 years influence the rates of stroke, coronary heart disease, and mortality?
Can treatment with a diuretic or beta-blocker reduce the risk of stroke, coronary heart disease, and death in older patients with hypertension?
Does antihypertensive treatment lower the risk of fatal and non-fatal stroke in patients with isolated systolic hypertension? Are beta-blockers and diuretics better than placebo for decreasing the rates of stroke, myocardial infarction, and other cardiovascular endpoints in patients aged 70-84 years?
This trial investigated the relationships between three diastolic blood pressure levels (≤ 90, ≤ 85, ≤ 80 mmHg) and cardiovascular morbidity and mortality as well as the effect of low-dose ASS (75 mg/d) on morbidity and mortality.
Are drugs such as amlodipine, lisinopril, and doxazosine better than chlorthalidone for reducing the rate and speed of progression of coronary heart disease? Does antihypertensive treatment lower the risk of stroke and other cardiovascular complications in patients with isolated systolic hypertension?
Does antihypertensive treatment lower the risk of stroke and other cardiovascular complications in patients with isolated systolic hypertension?
What is the effect of long-term treatment with an ACE inhibitor on the rate of stroke in patients who have already had a stroke or a TIA?
The influence of treatment with verapamil or atenolol on mortality, myocardial infarction, and stroke in patients with coronary heart disease and hypertension Does treatment with candesartan decrease the rate of cardiovascular events, cognitive deficit, or dementia in older patients with mild or moderate hypertension? What is the effect of atenolol + thiazide compared with amlodipine + perindopril on the rates von myocardial infarction and coronary heart disease? What is the effect of a combination of a low-dose diuretic and a low-dose calcium antagonist compared with monotherapy with a a low-dose diuretic on the rates of stroke and other cardiovascular events in Chinese patients?
Comparison of intensive blood pressure-lowering treatment (<120 mmHg) and standard treatment (<140 mmHg) in diabetics Effect of treatment with indapamide ± perindopril or placebo on the endpoints stroke, cardiovascular events, and mortality in patients aged 80 years and over with systolic blood pressure of 160 mmHg or higher Comparison of intensive treatment (systolic blood pressure <140 mmHg) and moderate treatment (systolic blood pressure 140 to 160 mmHg) on the endpoints stroke, cardiovascular events, and renal failure Efficacy and safety of a fixed combination of perindopril and indapamide for lowering the blood pressure of patients with diabetes mellitus type 2 in in the age groups below 65, 65 to 74, and 75 years or older Is intensive treatment (systolic blood pressure <140 mmHg) superior to moderate treatment (systolic blood pressure 140-<150 mmHg) for reducing cardiovascular mortality in older patients with isolated systolic hypertension?
Comparison of intensive treatment (systolic blood pressure <130 mmHg)and standard treatment (systolic blood pressure <140 mmHg) on left ventricular hypertrophy in non-diabetics Effect of intensive blood pressure-lowering treatment (<120 mmHg) compared with standard treatment (<140 mmHg) on the endpoints myocardial infarction, cardiovascular events, and mortality 
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